1 Research Way
Princeton, NJ 08540
United States
609 642 6670
https://www.pmvpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 63
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. David H. Mack Ph.D. | Co-Founder, CEO, President & Director | 881.08k | N/A | 1962 |
Dr. Arnold J. Levine Ph.D. | Co-Founder, Director & Member of Scientific Advisory Board | 140k | N/A | 1940 |
Dr. Marc Fellous M.D. | Senior VP and Head of Clinical Development & Medical Affairs | N/A | N/A | N/A |
Ms. Laura De Leon | VP & Head of Clinical Operations | N/A | N/A | N/A |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
PMV Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 7; Compensation: 8.